Cowen Sees 100% Upside For This Medical Device Firm

by Vandana Singh, Benzinga Editor

September 3, 2021 1:00 PM | 1 min read |

Cowen has raised Impel NeuroPharma Inc's IMPL price target to $55 from $35, with an Outperform rating, after the FDA approved Trudhesa for the acute treatment of migraine.
The analyst sees more than 100% upside for the stock.
Related Content: FDA Gives Nod To Nasal Spray Migraine Treatment From Impel NeuroPharma.
The "clean label" came in line with expectations, analyst Ken Cacciatore tells investors in a research note.
The analyst believes Trudhesa's "differential delivery" should provide a "much-needed" acute migraine option into this "extremely" large market.
Price Action: IMPL stock is up 17.2% at $27.10 during the market session on the last check Friday.

Posted In:

Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.